Evidence map›Paper›PMID 41226363›Full record

ArticleInternational journal of molecular sciences2025

Comparative Analysis of Cholinergic Machinery in Carcinomas: Discovery of Membrane-Tethered ChAT as Evidence for Surface-Based ACh Synthesis in Neuroblastoma Cells.

Banita Thakur, Samar Tarazi, Lada Doležalová, Homira Behbahani, Taher Darreh-Shori

Abstract readComparative Study
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Banita ThakurDivision of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institutet, SE-141 86 Stockholm, Sweden.
Samar TaraziDivision of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institutet, SE-141 86 Stockholm, Sweden.ORCID 0000-0002-2374-5887
Lada DoležalováDivision of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institutet, SE-141 86 Stockholm, Sweden.
Homira BehbahaniDivision of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institutet, SE-141 86 Stockholm, Sweden.
Taher Darreh-ShoriDivision of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institutet, SE-141 86 Stockholm, Sweden.

Funding

Åhlén-FoundationAlzheimer´s Association AARG-24-1310046Dementia Foundation (Demensfonden)Foundation for Old Servants (Gamla Tjänarinnor)Frimurarna Foundationgrant from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement ALF Med N 20200330Gun and Bertil Stohnes FoundationKarolinska Institutet´s Research FoundationsMagnus Bergvalls FoundationOlle Engkvist Byggmästare Foundationthe Stockholm Cancer Society #221212, #241282 and #221383the Swedish Cancer Society #CAN2021/1469, and # 24 3793Ulla-Carin Linquist Foundation for ALS research
6 · The paper itself

Abstract

The cholinergic system is one of the most ancient and widespread signaling systems in the body, implicated in a range of pathological conditions-from neurodegenerative disorders to cancer. Given its broad relevance, there is growing interest in characterizing this system across diverse cellular models to enable drug screening, mechanistic studies, and exploration of new therapeutic avenues. In this study, we investigated four cancer cell lines: one of neuroblastoma origin previously used in cholinergic signaling studies (SH-SY5Y), one non-small cell lung adenocarcinoma line (A549), and two small cell lung carcinoma lines (H69 and H82). We assessed the expression and localization of key components of the cholinergic system, along with the cellular capacity for acetylcholine (ACh) synthesis and release. Whole-cell flow cytometry following membrane permeabilization revealed that all cell lines expressed the ACh-synthesizing enzyme choline acetyltransferase (ChAT). HPLC-MS analysis confirmed that ChAT was functionally active, as all cell lines synthesized and released ACh into the conditioned media, suggesting the presence of autocrine and/or paracrine ACh signaling circuits, consistent with previous reports. The cell lines also demonstrated choline uptake, indicative of functional choline and/or organic cation transporters. Additionally, all lines expressed the ACh-degrading enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), as well as the alfa seven (α7) nicotinic and M1 muscarinic ACh receptor subtypes. Notably, flow cytometry of intact SH-SY5Y cells revealed two novel findings: (1) ChAT was localized to the extracellular membrane, a feature not observed in the lung cancer cell lines, and (2) BChE, rather than AChE, was the predominant membrane-bound ACh-degrading enzyme. These results were corroborated by both whole-cell and surface-confocal microscopy. In conclusion, our findings suggest that a functional cholinergic phenotype is a shared feature of several carcinoma cell lines, potentially serving as a survival checkpoint that could be therapeutically explored. The discovery of extracellular membrane-bound ChAT uniquely in neuroblastoma SH-SY5Y cells points to a novel form of in situ ACh signaling that warrants further investigation.

Indexed as

AcetylcholineCholine O-AcetyltransferaseNeuroblastomaAcetylcholinesteraseButyrylcholinesteraseCell Line, TumorCell MembraneCholineHumansSignal TransductionAcetylcholineAcetylcholinesteraseButyrylcholinesteraseCholineCholine O-Acetyltransferaseacetylcholine (ACh)Alzheimer’s Disease (AD)amyotrophic lateral sclerosis (ALS)cancercholine acetyltransferase (ChAT)cholinergic systemconfocal microscopyflow cytometrylung cancerneuroblastomaneurodegeneration

Identifiers

PMID41226363
PMCPMC12608971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.